Top Story

Weill Cornell Medicine/NewYork-Presbyterian neuro-oncologist receives NIH’s Pioneer Award

October 14, 2017

Howard A. Fine, MD, received a 5-year, $6 million NIH Director’s Pioneer Award for brain cancer research.

Fine — an internationally recognized neuro-oncologist — is founding director of the Brain Tumor Center and chief of the division of neuro-oncology at Weill Cornell Medicine and NewYork-Presbyterian.

NIH collaboration aims to identify, validate immunotherapy biomarkers

October 13, 2017
NIH launched the Partnership for Accelerating Cancer Therapies, a 5-year public-private research collaboration. The $215 million effort is part of the national cancer…
In the Journals Plus

Liquid biopsies predict response to immunotherapy

October 5, 2017
Patients with a higher number of DNA alterations detected by a liquid biopsy appeared more likely to respond to immune checkpoint inhibitors, according to retrospective…
In the Journals Plus

ASCO, Friends of Cancer Research: Trial eligibility criteria should ‘promote culture of inclusion’

October 2, 2017
ASCO and Friends of Cancer Research today released recommendations to broaden eligibility criteria for cancer clinical trials. These recommendations — and a…
More Headlines »

What's Hot in Melanoma? Highlights from the HemOnc Today Melanoma and Cutaneous Malignancies 2017 Meeting

This activity is supported by an educational grant from Merck & Co, Inc.

The development and integration of targeted therapies, as well as immunotherapies, into clinical strategies for the…
More »

Baseball great Mike Schmidt became ‘concerned about dying’ after melanoma diagnosis

September 25, 2017
More »
Resource Centers
European Society for Medical Oncology Congress

European Society for Medical Oncology Congress


Bridging the Gap from Knowledge to Practice in CRPC

This activity is supported by educational funding provided by AbbVie Inc.; Astellas Scientific and Medical Affairs, Inc. and Medivation; and Sanofi US.

The selection of therapy for patients with castration-resistant prostate cancer (CRPC) remains challenging. Review…
More »